Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies

Vox Sanguinis

Volumn 77, Issue 3, 1999, Pages 131-136

  Mariani, G ^m   Testa, M G ⁿ   Di Paolantonio, T ^a   Molskov Bech, R ^a   Hedner, U ^a   Roberts, H ^b   Stubb, J ^c   Ratnoff, O ^d   Greenberg, A L ^e   Hirsch, K ^f   Coba, E ^g   Fort, J ^h   Ewing, N ⁱ   Ingerslev, J ^j   Pefkarou, A ^h   De Bruyne, J ^k   Duraisamy, G ^l  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF ALABAMA   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e Broward Medical Center   (United States)

^f Department of Anesthesiology   (United States)

^g University Medical Center   (United States)

^h Children's Hospital   (United States)

ⁱ HUNTINGTON MEMORIAL HOSPITAL   (United States)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

^k UNIVERSITY OF MALAYSIA   (Malaysia)

^l HOSPITAL KUALA LUMPUR   (Malaysia)

^m UNIVERSITY OF PALERMO   (Italy)

ⁿ Medical School ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMARTHROSIS; HEMOSTASIS; HUMAN; INFANT; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTHROMBIN TIME; SURGERY;

ADULT; AGED; AGED, 80 AND OVER; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VII DEFICIENCY; FACTOR VIIA; HEMARTHROSIS; HEMOSTASIS; HUMANS; INFANT; ISOANTIBODIES; MALE; MIDDLE AGED; PROTHROMBIN; RECOMBINANT PROTEINS; THROMBIN; TIME FACTORS;

EID: 0032721725     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1159/000031091     Document Type: Article

References (24)

1. Mariani G, Mazzucconi MG: Factor VII congenital deficiency. Clinical picture and classification of the variants. Haemostasis 1983;13: 169-177.
2. Biggs R, Denson KWE: The fate of prothrombin and factors VII, IX and X transfused to patients deficient in these factors. Br J Haematol 1963;9:532-537.
3. Gilchrist GC, Ekert H, Shambrom E, Hammond D: Evaluation of a new concentrate for the treatment of factor IX deficiencies. N Engl J Med 1969;280:291-293.
4. Kelleher JF, Gomperts E, Davis W, Steingart R, Miller R, Bessette J: Selection of replacement therapy for patients with severe factor VII deficiency. Am J Pediatr Hematol/Oncol 1986;8:318-323.
5. Koehler M, Hellestern P, Pindur G, Wenzel E, von Blohn G: Factor VII half-life after transfusion of a steam-treated prothrombin complex concentrate in a patient with homozygous factor VII deficieny. Vox Sang 1989;56:200-201.
6. Mariani G, Mannucci PM, Mazzucconi MG, Capitanio A: Treatment of factor VII deficieny with a new concentrate. Thromb Haemost 1978;39:675-681.
7. Seligsohn U, Kasper CK, Osterud B, Rapaport IS: Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979;53:828-837.
8. Mariani G, Bouma BN, Mazzucconi MG, Avvisati G, Di Nucci GD, Corrao D, Mandelli F: Contact activation and factor VII after the use of an activated prothrombin complex concentrate (FEIBA) in hemophiliacs with inhibitors. Thromb Res 1983;31:475-489.
9. Hedner U, Kisiel W: Use of human factor VIIa in tretament of two hemophilia A patients with high titer inhibitors. J Clin Invest 1983;71: 1836-1837.
10. Thim L, Bjoern S, Christensen M, Nicolaisen EM, Lunde-Hansen T, Pedersen AH, Hedner U: Amino-acid sequence and post-translational modifications of human factor Vila from plasma and transfected baby hamster kidney cells. Biochemestry 1988;27:7785-7793.
11. Hedner U, Glazer S, Pingel K, Alberts KA, Blomback M, Schulman S, Johnsson H: Successful use of recombinant factor VII in patient with severe haemophilia A during synovectomy Lancet 1988;ii:1193.
12. Macik GB, Hohneker H, Roberts H, Griffin AM: The use of recombinant activated factor VII for treatment of a retropharingeal haemorrhage in a hemophilic patient with a high liter inhibitor. Am J Hematol 1989;32:232-234.
13. Schmidt ML, Smith HE, Gamerman S, Di Michele D, Glazer S, Scott JP: Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX deficient patient with an inhibitor. Br J Haematol 1991;78:460-463.
14. Hedner U, Felstedt M, Glazer S: Recombinant FVIIa in hemophilia treatment; In Hemophilia and von Willebrand's Disease in the 1990s. Luhser JM and Kessler CM (eds). Amsterdam, Elsevier Science Publishers, 1991.
15. Hedner U, Glazer S: Management of hemophilia patients with inhibitors. Hematol Oncol Clin North Am 1992;6:1035-1046.
16. Bell BA, Birch K, Glazer S: Experience with recombinant factor VIIa in an infant hemophiliac with inhibitors to FVIII:C undergoing emergency central line replacement. A case report. Am J Pediatr Hematol Oncol 1993;15:77-79.
17. Ingerslev J, Sneppen O, Knudsen L, Sindet-Pedersen S: Efficacy of recombinant FVIIa (rVIIa) in surgical procedures in hemophilia A patients with inhibitors and congenital factor VII deficiency; in Scharrer E. Schramm (eds.): Haemophilia-Symposium Proceedings, Hamburg. Berlin, Springer, 1994, pp 122-125.
18. Bech R, Nicolaisen EM, Anderson PM, Glazer S, Hedner U: Recombinant factor VIIa for the treatment of congenital factor VII deficient patients (abstract). Thromb Haemost 1989;62:55.
19. Ragni MV, Lewis JH, Spero JA, Hasiba U: Factor VII deficieicy. Am J Hematol 1981;10: 79-88.
20. Agrawal BL, Zelkowitz C, Hlecto P: Acute myocardial infarction in a young hemophilic patient during therapy with factor IX concentate and epsilon-aminocaproic acid. J. Pediatr 1981;98:931-933.
21. Fuerth JH, Mahrer P: Myocardial infarction after factor IX therapy. JAMA 1981;245:1455-1456.
22. Sellivan DW, Purdy LJ, Billingham M, Glader BE: Fatal myocardial infarction following therapy with prothrombin complex concentrates in a young man with hemophilia A. Pediatrics 1984;74:279-281.
23. Hasegawa DK, Edson JR: Thrombocytopenia and hypofibrinogenemia following activated prothrombin complex concentrate therapy in a patient with hemophilia A and factor VIII inhibitor. Progr Clin Biol Res 1984;150:386-387.
24. Hadley T, Djulbegovich B: Disseminated intravascular coagulation after factor IX complex resolved using purified factor IX concentrate. Ann Intern Med 1991;115:621-622.